The U.S. District Court for the District of Delaware has ruled that DexCom’s (DXCM) G6 continuous glucose monitors infringe one of three patents held by an Abbott (ABT) subsidiary, but the federal jury couldn’t reach a verdict on infringement of a fourth patent related to the devices, which track blood sugar levels without fingersticks, Bloomberg Law’s Christopher Yasiejko reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- TipRanks’ ‘Perfect 10’ List: Analysts Pound the Table on These Top-Scoring Stocks
- Oracle, Dollar General upgraded: Wall Street’s top analyst calls
- RBC starts DexCom with Outperform on multi-year runway
- DexCom initiated with an Outperform at RBC Capital
- Early notable gainers among liquid option names on March 6th
